TechneScan Sestamibi: Uses, Dosage & Side Effects
A cold kit for radiolabeling with sodium pertechnetate (99mTc) to produce technetium-99m sestamibi injection - a lipophilic cationic radiopharmaceutical for diagnostic myocardial perfusion imaging, parathyroid scintigraphy and breast scintigraphy
TechneScan Sestamibi is a non-radioactive (“cold”) kit that, once reconstituted with sterile sodium pertechnetate (99mTc) in a licensed radiopharmacy, yields the diagnostic radiopharmaceutical technetium-99m sestamibi (also called 99mTc-MIBI). The injectable solution is used for three established diagnostic purposes: myocardial perfusion imaging to detect and characterise coronary artery disease and myocardial viability; parathyroid scintigraphy to localise hyperfunctioning parathyroid tissue before surgery; and breast scintigraphy (scintimammography or molecular breast imaging) to characterise equivocal breast lesions as an adjunct to mammography and ultrasound. TechneScan Sestamibi is administered only by trained nuclear medicine professionals in hospitals or specialised imaging centres, requires a prescription, and is used for diagnostic imaging rather than for treatment of disease.
Quick Facts: TechneScan Sestamibi
Key Takeaways
- TechneScan Sestamibi is a diagnostic radiopharmaceutical kit that, after reconstitution with sodium pertechnetate (99mTc), produces technetium-99m sestamibi injection - a lipophilic cationic complex that accumulates in tissues with high mitochondrial density and blood flow.
- Its principal clinical uses are myocardial perfusion imaging to evaluate coronary artery disease and myocardial viability, parathyroid scintigraphy to localise adenomas before surgery, and molecular breast imaging as an adjunct to conventional breast imaging.
- The kit is never administered directly; it must be reconstituted and heated in a licensed radiopharmacy and undergo quality control before the final 99mTc-sestamibi injection is drawn into a shielded syringe and given as a slow intravenous bolus.
- TechneScan Sestamibi is very well tolerated - the most common side effect is a transient metallic or bitter taste; serious hypersensitivity reactions are rare, and the main safety consideration is the small amount of ionizing radiation delivered.
- Pregnancy is a relative contraindication and breastfeeding must be interrupted for at least 24 hours; caffeine and certain cardiac medications may need to be withheld before cardiac stress testing to ensure diagnostic image quality.
What Is TechneScan Sestamibi and What Is It Used For?
TechneScan Sestamibi is supplied as a sterile, lyophilized (freeze-dried) powder in a multidose vial. It contains the non-radioactive ligand sestamibi - chemically tetrakis(2-methoxyisobutylisonitrile)copper(I) tetrafluoroborate, often abbreviated as MIBI - together with stannous chloride dihydrate as a reducing agent and buffering excipients. In this form the kit has no imaging or pharmacological activity on its own; it is the precursor used by a licensed radiopharmacy to prepare the actual radiopharmaceutical.
The final medicine, technetium-99m sestamibi injection, is formed by adding a measured volume of sterile sodium pertechnetate (99mTc) eluate - obtained from a 99Mo/99mTc generator - into the vial and heating the mixture in a boiling water bath or validated heating block for approximately 10 minutes. During this step the stannous ions reduce Tc(VII) to Tc(I), which displaces the copper at the centre of the ligand to form the stable, lipophilic monocation [99mTc(MIBI)6]+. After cooling and rigorous quality control (radiochemical purity, appearance and pH testing), the ready-to-use solution is drawn into a shielded syringe and dispensed for patient administration.
Once injected intravenously, 99mTc-sestamibi distributes throughout the body according to regional blood flow and is preferentially taken up by cells with large numbers of mitochondria and strongly negative transmembrane potentials - a property that makes it especially useful for imaging metabolically active tissues such as myocardium, hyperfunctioning parathyroid cells and certain tumours. The tracer emits gamma photons of 140 keV, which are ideal for detection by a modern gamma camera using either planar imaging, single-photon emission computed tomography (SPECT) or hybrid SPECT/CT. The combination of physiological targeting and image reconstruction allows physicians to visualise anatomy, perfusion and function simultaneously.
TechneScan Sestamibi is approved by the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), the UK Medicines and Healthcare products Regulatory Agency (MHRA) and numerous other regulatory authorities worldwide for the following diagnostic indications:
- Myocardial perfusion imaging (MPI): 99mTc-sestamibi is used to detect and assess coronary artery disease (CAD), to localise regions of reversible or fixed perfusion abnormalities (ischaemia versus infarction), and to help stratify prognostic risk before and after percutaneous or surgical revascularisation. The test is typically performed as a combined rest and stress study, with stress induced by exercise or pharmacological agents such as adenosine, dipyridamole or regadenoson.
- Assessment of myocardial viability: In patients with known reduced left ventricular function, sestamibi uptake correlates with preserved cellular integrity and mitochondrial function. Areas that take up tracer despite reduced contraction are considered hibernating or stunned and may recover after revascularisation, whereas non-viable scar shows minimal uptake.
- ECG-gated SPECT imaging of left ventricular function: When images are acquired with ECG gating, the data can be reconstructed into a cine loop that provides quantitative measurements of left ventricular ejection fraction, end-diastolic and end-systolic volumes, and regional wall motion - all from a single injection.
- Parathyroid scintigraphy: Because abnormal parathyroid tissue has a high mitochondrial density (due to oxyphil cells) and retains 99mTc-sestamibi longer than adjacent thyroid tissue, the tracer is widely used to localise parathyroid adenomas and hyperplasia before minimally invasive parathyroidectomy in primary and secondary hyperparathyroidism. Dual-phase planar imaging, dual-tracer subtraction techniques and SPECT/CT all rely on this differential washout.
- Molecular breast imaging (breast scintigraphy, scintimammography): 99mTc-sestamibi is taken up by many breast malignancies because of their increased blood flow, mitochondrial content and membrane potential. The tracer is used as an adjunct to mammography and ultrasound in women with dense breasts, in those with indeterminate or discordant findings, or when contrast-enhanced MRI is contraindicated.
Several additional investigational and off-label uses have been described in the literature, including evaluation of multidrug resistance in tumours (because P-glycoprotein actively effluxes sestamibi from some cancer cells), pre-operative localisation of functioning adrenal lesions, and characterisation of thyroid and bone lesions, but these are not part of the core licensed indications and vary by country.
Unlike older lipophilic cardiac tracers, 99mTc-sestamibi is retained within cells primarily by electrostatic sequestration inside mitochondria rather than by active metabolism. This makes it a marker of both perfusion (how much tracer arrives) and cellular integrity (whether healthy mitochondria are present to retain it). In practice, this single injection provides two layers of diagnostic information about the heart muscle.
What Should You Know Before Receiving TechneScan Sestamibi?
Contraindications
There are relatively few absolute contraindications to 99mTc-sestamibi itself, because the amount of active ingredient delivered is extremely small. However, several situations require that the examination be deferred, replaced with an alternative, or performed only with additional precautions.
- Hypersensitivity: Patients with a known hypersensitivity to the active substance, any of the excipients (stannous chloride dihydrate, sodium citrate, cysteine, mannitol) or to 99mTc-containing products should not receive TechneScan Sestamibi. Re-exposure after a previous anaphylactic or severe cutaneous reaction is contraindicated.
- Pregnancy (relative): The examination should not be performed during pregnancy unless it is clinically essential and no non-radiation alternative is available. If imaging is unavoidable, the lowest administered activity consistent with obtaining diagnostic-quality images should be used.
- Severe pharmacological stress contraindications: When the sestamibi MPI is combined with pharmacological stress (dipyridamole, adenosine or regadenoson), the usual contraindications to those stress agents apply - including severe reactive airway disease, high-grade atrioventricular block without a pacemaker and known hypersensitivity to the stress agent. Exercise stress testing has its own contraindications (decompensated heart failure, unstable angina, severe aortic stenosis, uncontrolled hypertension).
Warnings and Precautions
Although rare, serious hypersensitivity reactions - including urticaria, angio-oedema, bronchospasm, hypotension and anaphylactic shock - have been reported after administration of 99mTc-sestamibi. The nuclear medicine facility must have appropriate resuscitation equipment, medications and trained personnel immediately available. Patients should be observed for at least 15-30 minutes after injection, and any signs of reaction (rash, itching, difficulty breathing, swelling of the face or tongue) must be reported immediately.
Before your examination, inform the nuclear medicine team about each of the following:
- Ionizing radiation: 99mTc-sestamibi exposes the patient and staff to ionizing radiation. The radiation dose is carefully justified on the basis of clinical indication and the principle of as low as reasonably achievable (ALARA). Modern SPECT/CT systems, weight-based dosing and stress-first protocols can substantially reduce the effective dose.
- Severe hepatic or renal impairment: Excretion of 99mTc-sestamibi is predominantly hepatobiliary, with a smaller urinary component. In severe hepatic impairment hepatobiliary clearance may be prolonged, which can cause increased background activity over the inferior wall of the heart and reduce image quality. In severe renal impairment, urinary excretion is prolonged, leading to higher bladder and pelvic activity.
- Recent nuclear medicine or radiology examinations: Residual activity from other radiopharmaceuticals (e.g. 99mTc bone scan, 18F-FDG PET) or recent administration of gastrointestinal contrast agents may interfere with image interpretation. An appropriate interval between studies should be planned.
- Unstable clinical status: Patients with unstable angina, recent myocardial infarction (within 2-4 days), decompensated heart failure, severe aortic stenosis, acute pericarditis or uncontrolled arrhythmia should not undergo exercise or pharmacological stress testing until the underlying condition has been stabilised.
- Severe reactive airway disease: If the stress component of the MPI is pharmacological (adenosine, dipyridamole or regadenoson), patients with active bronchospasm or severe asthma/COPD may not be suitable candidates because these agents can provoke bronchoconstriction. Alternative stress strategies or tracers may be considered.
- Left bundle branch block or paced rhythm: In these patients, exercise-induced septal perfusion defects may occur as artefacts; pharmacological vasodilator stress is usually preferred to improve diagnostic accuracy.
- Recent large meals or caffeine intake: For cardiac indications, food and caffeine can affect tracer biodistribution and blunt the response to pharmacological vasodilators. Follow the fasting and caffeine-avoidance instructions given by the nuclear medicine department.
Patient Preparation
Proper preparation is one of the most important determinants of image quality and therefore of diagnostic accuracy. Requirements vary according to the indication:
- Myocardial perfusion imaging: Fast for 4-6 hours; avoid caffeine and methylxanthines (coffee, tea, cola, chocolate, theophylline, aminophylline) for 12-24 hours before pharmacological stress testing. The referring physician will advise whether cardiac medications such as beta-blockers, calcium channel blockers and nitrates should be withheld before exercise stress testing. Bring a list of current medications to the appointment.
- Parathyroid scintigraphy: Usually no fasting or special medication adjustments are required. If dual-tracer subtraction with iodine-123 or 99mTc-pertechnetate is planned, the department will advise on iodine avoidance and thyroid medication timing.
- Breast scintigraphy: Typically scheduled during days 2-10 of the menstrual cycle to minimise background breast parenchymal uptake. Avoid skin lotions, deodorants or creams on the chest wall on the day of the scan. Wear a two-piece outfit for convenience.
Pregnancy and Breastfeeding
If you are or might be pregnant, you must inform the nuclear medicine team before any radiopharmaceutical is administered. Diagnostic imaging with ionizing radiation is generally avoided during pregnancy because of potential harm to the developing fetus, including a small theoretical increase in childhood cancer risk. When a sestamibi examination is clinically unavoidable, the minimum administered activity consistent with obtaining a diagnostic study is used, hydration is encouraged to reduce bladder dose to the fetus, and the benefits and risks are documented.
For breastfeeding mothers, breastfeeding should be interrupted after administration of 99mTc-sestamibi for at least 24 hours, with milk expressed during this interval discarded. Some national guidelines recommend a longer interval. Close contact with infants (e.g. holding for extended periods) should also be limited for the first few hours after injection, because 99mTc is excreted partly in saliva and urine and emits gamma radiation that can reach the infant.
Fertility is not known to be affected by the very small amounts of sestamibi or the short-lived radioisotope used. Nevertheless, radiation exposure of the gonads should be minimised wherever possible, particularly in younger patients and those who may later wish to conceive.
Children and Elderly
In paediatric patients, the administered activity of 99mTc-sestamibi is reduced proportionally to body weight according to the EANM Paediatric Dosage Card, and specific indications are uncommon outside of specialised centres. In elderly patients, no dose adjustment is required, but underlying cardiac or renal comorbidities may require additional precautions during stress testing.
Driving and Operating Machinery
99mTc-sestamibi itself does not impair alertness or reaction time. However, pharmacological stress agents and sedatives (if given) may cause dizziness, hypotension or drowsiness for a short period after the test. It is usually recommended that patients arrange to be accompanied home after any stress test and avoid driving immediately afterwards.
How Does TechneScan Sestamibi Interact with Other Drugs?
Pharmacokinetic interactions with 99mTc-sestamibi itself are uncommon because the injected amount of MIBI is tiny and below any threshold for enzyme induction or inhibition. Clinically important “interactions” are mostly physiological - that is, they affect the quality or interpretation of the image rather than the pharmacology of the tracer. It is essential to provide the nuclear medicine team with a complete current medication list, including over-the-counter products, herbal supplements and recent courses of treatment.
Major Interactions
| Interacting Agent | Effect on the Study | Clinical Management |
|---|---|---|
| Caffeine and methylxanthines (coffee, tea, cola, chocolate, theophylline, aminophylline) | Antagonise adenosine, dipyridamole and regadenoson at the A2A receptor, reducing coronary vasodilation and producing false-negative stress results. | Avoid for at least 12-24 hours before pharmacological stress testing; check serum theophylline if uncertain. |
| Beta-blockers (atenolol, metoprolol, bisoprolol) | Blunt heart-rate response during exercise stress, reducing sensitivity for inducible ischaemia. | Consider withholding for 24-48 hours before an exercise MPI if safe; not routinely withheld if the indication is to assess response on therapy. |
| Long-acting nitrates (isosorbide mononitrate, nitroglycerin patches) | Can temporarily reverse ischaemia-induced perfusion defects, masking coronary disease. | Usually withheld for 24 hours before stress testing when clinically safe. |
| Calcium channel blockers (diltiazem, verapamil) | Can blunt ischaemic response; verapamil additionally inhibits P-glycoprotein, altering tracer biodistribution. | May be withheld for exercise testing; less critical for pharmacological stress. |
| Dipyridamole (including over-the-counter combinations with aspirin) | Pre-existing dipyridamole may limit the incremental response to additional pharmacological vasodilators. | Usually withheld for 48 hours before stress testing; inform the team. |
| P-glycoprotein inhibitors (ciclosporin, verapamil, quinidine, erythromycin) | Reduce efflux of sestamibi from tumour cells, increasing apparent tumour uptake; can affect breast and parathyroid imaging interpretation and multidrug-resistance studies. | Note on the request form; findings must be interpreted in light of the medication list. |
Minor and Situational Interactions
| Interacting Agent | Effect on the Study | Clinical Management |
|---|---|---|
| Insulin and glucose | Can shift cardiac substrate utilisation and modestly alter tracer uptake, particularly in diabetic patients. | Standardised pre-test meals and dosing; diabetes management protocols are followed. |
| Anthracyclines (doxorubicin, daunorubicin) and other cardiotoxic chemotherapy | Can cause changes in LVEF and regional wall motion independent of ischaemia; baseline studies are often obtained before treatment. | Interpret with treatment history; sestamibi ECG-gated SPECT can be used for serial LVEF monitoring. |
| Granulocyte colony-stimulating factor (filgrastim) | Can increase bone marrow and spleen uptake of several tracers; effect on sestamibi imaging is usually modest. | Note on the request form. |
| Recent gadolinium-based MRI contrast or iodinated contrast | No pharmacological interaction with sestamibi, but recent contrast exposure should be documented for radiation and renal safety planning. | Review renal function before repeated contrast exposure. |
| Iodine-containing agents (thyroid medications, iodinated contrast) | Not relevant for sestamibi alone but important when dual-tracer parathyroid imaging uses 123I or pertechnetate; iodine can suppress thyroid uptake. | Follow the department’s iodine-avoidance protocol when dual-tracer imaging is planned. |
Because withdrawal of cardiac medications can itself precipitate ischaemia or hypertensive crisis, never stop or alter prescribed medications on your own. All decisions about which drugs to hold before a sestamibi study are made by the referring cardiologist or nuclear medicine physician based on your individual risk profile.
What Is the Correct Dosage of TechneScan Sestamibi?
Because TechneScan Sestamibi is a diagnostic radiopharmaceutical, the “dose” is expressed as an administered activity in megabecquerels (MBq) or millicuries (mCi), not as a mass of active substance. The amount of sestamibi mass actually delivered is extremely small - in the microgram range - and has no direct pharmacological action. The aim of dosing is to deliver sufficient photon counts for a diagnostic study while keeping the radiation exposure as low as reasonably achievable. Published ranges differ slightly between the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the FDA label and national regulatory authorities; each department maintains its own validated protocols.
Adults
Myocardial Perfusion Imaging - One-Day Rest/Stress Protocol
Rest injection: 250-500 MBq (7-14 mCi) intravenously, with imaging started 45-60 minutes later.
Stress injection (same day): 600-1100 MBq (16-30 mCi) intravenously at peak exercise or during peak vasodilator effect, with imaging started 15-30 minutes later.
The higher stress activity allows the stress images to dominate over residual rest activity. Total effective dose is typically around 8-10 mSv.
Myocardial Perfusion Imaging - Two-Day Rest/Stress Protocol
Day 1 (rest or stress): 400-600 MBq (11-16 mCi) intravenously.
Day 2 (the other arm of the study): 400-600 MBq (11-16 mCi) intravenously.
Useful in larger patients or when better count statistics are needed; splitting the study over two days allows each image set to be acquired without carry-over activity and generally delivers a slightly lower total effective dose than a one-day protocol.
Stress-Only or Stress-First Protocols
Stress injection: 400-740 MBq (11-20 mCi). If the stress study is completely normal, rest imaging may be omitted, reducing the effective dose to around 4-5 mSv.
Increasingly adopted with modern high-sensitivity cadmium-zinc-telluride (CZT) cameras and SPECT/CT systems.
Parathyroid Scintigraphy
Dose: 8-10 MBq/kg (typically 500-900 MBq total for a 70 kg adult) intravenously.
Imaging: Early planar imaging at 10-15 minutes, delayed imaging at 1.5-3 hours; SPECT or SPECT/CT is usually added for anatomical localisation.
Dual-tracer subtraction imaging with 123I-sodium iodide or 99mTc-pertechnetate for thyroid subtraction is offered in some centres.
Breast Scintigraphy (Molecular Breast Imaging)
Dose: 740-1110 MBq (20-30 mCi) with a conventional Anger camera, or 150-300 MBq (4-8 mCi) with dedicated dual-head breast-specific gamma imaging systems.
Imaging: Mild breast compression with planar views of each breast in standard mammographic projections; usually performed during days 2-10 of the menstrual cycle to minimise background uptake.
Children
Paediatric dosing of 99mTc-sestamibi follows the EANM Paediatric Dosage Card, in which the administered activity is calculated from the reference adult activity multiplied by a weight-dependent coefficient. A typical activity for a 20 kg child undergoing a cardiac study is approximately 80-150 MBq (2-4 mCi), with appropriate adjustments for very small or very large children. Paediatric examinations should be performed only in centres experienced in paediatric nuclear medicine, and alternative imaging (echocardiography, cardiac MRI) is usually considered first.
Elderly
No specific dose adjustment is required purely on the basis of age. Weight-based dosing, modern camera technology and careful selection of rest-only or stress-only protocols should be used to minimise radiation exposure in older adults. Baseline renal function and comorbidities (particularly chronic kidney disease and heart failure) should be considered when planning the examination.
Kidney and Liver Impairment
No dose adjustment is required on the basis of kidney or liver function. However, in severe hepatic impairment hepatobiliary clearance is slowed, so delayed imaging or repeat imaging after a fatty meal may be needed to clear gallbladder and bowel background activity. In severe renal impairment urinary excretion is prolonged; increased bladder activity may affect pelvic images and should be mitigated by hydration and frequent voiding where possible.
Missed Dose
TechneScan Sestamibi is administered only once per examination under direct supervision of a nuclear medicine physician or technologist, so the concept of a “missed dose” does not apply. If an appointment is missed, a new appointment is scheduled and the radiopharmaceutical is prepared freshly on the day of the study, because the short half-life of 99mTc (6.02 hours) means that an unused dose rapidly decays.
Overdose
An overdose of radiation rather than of sestamibi is the main concern if an inadvertent overactivity is administered. Actions to reduce radiation exposure include encouraging oral or intravenous hydration and frequent voiding to accelerate urinary clearance, and encouraging gallbladder emptying with a fatty meal or cholecystokinin to accelerate hepatobiliary clearance. There is no specific pharmacological antidote for the sestamibi molecule itself, as the administered mass is too small to cause systemic toxicity. If an overdose is suspected, the radiation protection officer and medical physicist should be contacted immediately.
How TechneScan Sestamibi Is Given
The final 99mTc-sestamibi injection is administered as a slow intravenous bolus into a peripheral vein, typically via an indwelling cannula. To reduce the risk of extravasation, the nuclear medicine technologist verifies cannula patency with a saline flush before the activity is injected, and observes the injection site carefully during administration. After injection, patients are usually asked to drink plenty of fluids and to void frequently to reduce bladder and gonadal radiation dose.
For cardiac studies, a fatty meal or drink (e.g. milk, yogurt) may be given between injection and imaging to promote gallbladder contraction and clear subdiaphragmatic activity. Imaging begins once adequate clearance has occurred - this is typically 15-30 minutes after stress injection, 45-60 minutes after rest injection for cardiac studies, 10-15 minutes and again 1.5-3 hours after injection for parathyroid imaging, and 5-10 minutes after injection for molecular breast imaging.
TechneScan Sestamibi is always prepared and administered by authorised personnel in a licensed nuclear medicine facility. It is never dispensed to patients for home use. Appropriate personal protective equipment, shielded syringes, radiation monitoring and trained staff are required at every step from radiolabeling to disposal.
What Are the Side Effects of TechneScan Sestamibi?
Because the administered mass of sestamibi is very small (microgram quantities), pharmacologically mediated side effects are infrequent. Most symptoms experienced during a 99mTc-sestamibi study are related to the stress component (exercise or pharmacological vasodilators) rather than to the tracer itself, or to the radiation dose, which is a small incremental risk that must be justified against the diagnostic benefit. The frequency categories below follow EMA conventions and are derived from the summary of product characteristics and post-marketing surveillance.
Frequencies of Reported Adverse Reactions
Very Common
May affect more than 1 in 10 people
- Transient metallic or bitter taste shortly after injection (dysgeusia)
- Altered sense of smell (parosmia), typically lasting a few minutes
Common
May affect up to 1 in 10 people
- Headache
- Mild nausea
- Chest pain or tightness (often related to concurrent stress testing)
- Flushing and warmth sensation
- Transient injection-site discomfort
Uncommon
May affect up to 1 in 100 people
- Dizziness or lightheadedness
- Palpitations or transient arrhythmias (mostly related to stress)
- Abdominal pain, dyspepsia or vomiting
- Skin rash, itching (pruritus) or urticaria
- Paraesthesia (tingling in hands or feet)
- Fatigue
- Fever or flu-like symptoms
- Dry mouth
- Transient hypotension or hypertension
Rare
May affect up to 1 in 1,000 people
- Serious hypersensitivity reactions including angio-oedema and anaphylaxis
- Bronchospasm
- Seizures
- Syncope
- Severe skin reactions (erythema multiforme, exfoliative rash)
- Severe arrhythmias (ventricular tachycardia, atrial fibrillation) during stress testing
- Myocardial infarction during stress testing (in susceptible individuals)
Not Known
Frequency cannot be estimated from available data
- Extravasation injury (local pain, erythema, tissue damage at the injection site if the dose leaks outside the vein)
- Transient ST-segment changes or conduction abnormalities related to stress
- Very rare theoretical long-term stochastic effects of ionizing radiation (e.g. induction of malignancy), the magnitude of which is balanced by the expected diagnostic benefit
Radiation Exposure
The effective radiation dose delivered to an adult undergoing a typical 99mTc-sestamibi study ranges from approximately 4-5 mSv for a stress-only protocol with a modern CZT camera to approximately 8-12 mSv for a traditional one-day rest/stress protocol with a conventional camera. For context, the average natural background radiation dose in many countries is 2-3 mSv per year. The lifetime attributable risk of cancer from a single diagnostic sestamibi study is small - on the order of 1 in 2,000 to 1 in 5,000 depending on age, sex and exact dose - and must always be weighed against the diagnostic benefit, which often includes direct impact on therapy and survival.
Organs receiving the highest absorbed dose include the gallbladder wall, upper and lower large intestine, urinary bladder wall and kidneys. Hydration, frequent voiding and cholecystogogue meals help to reduce these local doses. Modern imaging protocols, including weight-based dose reduction, stress-first approaches and dose-reducing CZT and SPECT/CT technology, continue to drive down patient exposure substantially below the figures given in older prescribing information.
If you experience any side effects during or after your sestamibi examination, including those not listed above, inform the nuclear medicine team immediately. In most countries suspected adverse reactions can also be reported to the relevant national pharmacovigilance authority (for example, the EMA in Europe, the FDA MedWatch program in the United States, or the MHRA Yellow Card Scheme in the United Kingdom).
How Should TechneScan Sestamibi Be Stored?
Storage and handling are the responsibility of the radiopharmacy and nuclear medicine department and are strictly governed by pharmaceutical, radiation protection and transport regulations. Patients will not encounter storage decisions directly; the information below is provided for completeness and to help patients understand what happens behind the scenes.
- Unopened kit: Store below 25°C (or as specified on the label - some formulations recommend 2-8°C). Protect from light and do not freeze. Do not use after the expiry date printed on the vial label and outer carton.
- Reconstituted injection: After radiolabeling and quality control, store the solution at 2-25°C (depending on the specific product SmPC), protected from light and in a shielded container. Use within the validated shelf-life, which is typically up to 10 hours from reconstitution but may be shorter - always follow the product label and national pharmacopoeia requirements.
- Radiation protection: All handling takes place in a licensed radiopharmacy behind appropriate lead shielding. Syringes are dispensed in shielded transport containers, and waste is stored in shielded bins until it has decayed to background levels before disposal.
- Inspection: The solution should appear clear and colourless. Do not administer if particles, discoloration or damaged vials are observed. Radiochemical purity is confirmed by thin-layer chromatography or an equivalent method and must meet the SmPC threshold before patient administration.
- Waste disposal: Unused radiopharmaceutical and any contaminated materials are disposed of in accordance with national radiation protection regulations. Do not dispose of radiopharmaceuticals via household waste or wastewater.
What Does TechneScan Sestamibi Contain?
Active Substance
The active ingredient of the kit is tetrakis(2-methoxyisobutylisonitrile)copper(I) tetrafluoroborate, commonly referred to as sestamibi (from the abbreviation MIBI for methoxyisobutylisonitrile). Each vial typically contains 1.0 mg of the ligand, sufficient to produce multiple patient doses of 99mTc-sestamibi after reconstitution with a suitable volume of 99mTc-pertechnetate eluate. The exact amount of sestamibi delivered per patient is in the low microgram range and has no pharmacological activity by itself.
Inactive Ingredients (Excipients)
- Stannous chloride dihydrate - reducing agent that reduces Tc(VII) to Tc(I)
- Cysteine hydrochloride monohydrate - stabilising and chelating agent
- Sodium citrate dihydrate - buffering agent
- Mannitol - bulking agent and cryoprotectant for the lyophilized cake
The kit does not contain preservatives, antimicrobials or colouring agents. It does not contain lactose, gluten or ingredients of animal origin.
Appearance
TechneScan Sestamibi is supplied as a white to off-white lyophilized cake or powder in a multidose glass vial sealed with a rubber stopper and aluminium cap. After reconstitution with sodium pertechnetate (99mTc) and heating, the resulting technetium-99m sestamibi solution is a clear, colourless liquid free of particulate matter, with a pH of approximately 5.5. Each package contains 5 multidose vials (the exact pack size may vary by country).
Radionuclide Added During Preparation
The radionuclide technetium-99m (99mTc) is added to the kit in the radiopharmacy as sterile sodium pertechnetate (99mTc) injection, eluted from a regulated 99Mo/99mTc generator. Technetium-99m decays by isomeric transition with a physical half-life of 6.02 hours, emitting a near-monoenergetic 140 keV gamma photon that is ideally suited to gamma camera imaging. The short half-life and favourable photon energy are a major reason why 99mTc is the most widely used radionuclide in diagnostic nuclear medicine worldwide.
Marketing Authorisation Holder and Manufacturer
TechneScan Sestamibi is marketed by Curium Pharma, a leading international radiopharmaceutical company. Generic and brand-name equivalents of technetium-99m sestamibi are also marketed in many countries under other trade names, including Cardiolite (originally developed by DuPont/Bristol-Myers Squibb) and Miraluma for breast imaging. All formulations must meet the relevant European Pharmacopoeia, United States Pharmacopeia (USP) or national pharmacopoeia monograph for technetium (99mTc) sestamibi injection.
Frequently Asked Questions About TechneScan Sestamibi
TechneScan Sestamibi is a cold kit that, after reconstitution with sodium pertechnetate (99mTc), produces technetium-99m sestamibi (99mTc-MIBI) injection. It is used for three main diagnostic indications: myocardial perfusion imaging to detect coronary artery disease and assess myocardial viability, parathyroid scintigraphy to localise parathyroid adenomas and hyperplasia before surgery, and breast scintigraphy (scintimammography or molecular breast imaging) to characterise indeterminate breast lesions as an adjunct to mammography and ultrasound.
The radiolabeled solution is given as a slow intravenous injection through a small cannula by a nuclear medicine technologist. Imaging does not begin immediately - for cardiac studies it usually starts 15-60 minutes after injection, for parathyroid imaging at 10-15 minutes and again at 1.5-3 hours, and for breast scintigraphy 5-10 minutes after injection. The total time on the appointment day, including preparation, injection, waiting and image acquisition, is typically 2-4 hours for a cardiac stress test and 2-4 hours in total for parathyroid imaging that includes delayed views and SPECT/CT.
99mTc-sestamibi has been in clinical use since the early 1990s and is considered safe and well tolerated. The most common side effect is a brief metallic taste after injection, and serious hypersensitivity reactions are rare. The radiation exposure from a typical examination (approximately 4-12 mSv depending on the protocol) is comparable to other routine nuclear medicine scans and is low enough that the diagnostic benefit usually far outweighs the very small theoretical increase in long-term cancer risk. Modern cameras and weight-adjusted dosing have reduced doses substantially compared with older protocols.
For cardiac stress studies, you will usually be asked to fast for 4-6 hours and to avoid caffeine (coffee, tea, cola, chocolate) and theophylline-containing medications for at least 12-24 hours, because caffeine blocks the action of the pharmacological stress agents. The referring physician will advise whether cardiac medications such as beta-blockers, calcium channel blockers or nitrates should be withheld before an exercise test. For parathyroid scintigraphy no fasting is required, and for breast scintigraphy there are no dietary restrictions - but avoid skin lotions, deodorants and creams on the chest on the day of the scan, and prefer days 2-10 of your menstrual cycle if applicable.
99mTc-sestamibi is generally avoided during pregnancy because ionizing radiation can harm the developing fetus. If the examination is clinically essential and no non-radiation alternative exists (for example urgent assessment of acute chest pain that cannot be evaluated otherwise), the lowest diagnostic activity possible is used and maternal hydration is encouraged to reduce fetal exposure. Breastfeeding should be interrupted for at least 24 hours after injection, with expressed milk during this interval discarded; some national guidelines recommend a longer interval. Always tell the nuclear medicine team if you are or might be pregnant, or if you are breastfeeding.
After a 99mTc-sestamibi injection, most of the radioactivity is eliminated through hepatobiliary and urinary pathways. You will be encouraged to drink plenty of fluids and to empty your bladder frequently for the rest of the day to speed up clearance. For the first few hours it is sensible to limit prolonged close contact with pregnant women and young children as a precautionary measure. The 6-hour half-life of 99mTc means that radioactivity decays rapidly - approximately half every 6 hours - and after about 24 hours very little measurable activity remains in the body.
Meta-analyses of 99mTc-sestamibi SPECT myocardial perfusion imaging report typical sensitivities of 85-90% and specificities of 70-80% for detecting obstructive coronary artery disease, with accuracy that improves further with attenuation correction, ECG gating and modern SPECT/CT or CZT cameras. Stress MPI also provides powerful prognostic information: a normal stress perfusion scan in a patient with intermediate pre-test probability carries an annual risk of hard cardiac events below 1%. Diagnostic performance depends on patient factors (body habitus, prior infarction, left bundle branch block), stress adequacy and camera technology.
References
- European Medicines Agency (EMA). Summary of Product Characteristics for kits for radiopharmaceutical preparation of technetium (99mTc) sestamibi injection. Last updated 2025. Available from: EMA.
- U.S. Food and Drug Administration (FDA). Cardiolite (Technetium Tc-99m Sestamibi) Prescribing Information. Revised 2024. Available from: FDA Drug Label.
- Verberne HJ, Acampa W, Anagnostopoulos C, et al. EANM procedural guidelines for radionuclide myocardial perfusion imaging with SPECT and SPECT/CT: 2023 revision. Eur J Nucl Med Mol Imaging. 2023;50(6):1707-1745.
- Dorbala S, Ananthasubramaniam K, Armstrong IS, et al. Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging Guidelines: Instrumentation, Acquisition, Processing, and Interpretation. J Nucl Cardiol. 2018;25(5):1784-1846.
- Hindie E, Ugur O, Fuster D, et al. 2022 SNMMI Procedure Standard/EANM Practice Guideline for Parathyroid Imaging, Version 2.0. J Nucl Med. 2022;63(11):1840-1854.
- Hruska CB. Molecular Breast Imaging for Screening in Dense Breasts: State of the Art and Future Directions. AJR Am J Roentgenol. 2017;208(2):275-283.
- International Commission on Radiological Protection (ICRP). Publication 128: Radiation Dose to Patients from Radiopharmaceuticals: A Compendium of Current Information Related to Frequency and Dosimetry. Ann ICRP. 2015;44(2S):7-321.
- Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-477.
- Gnesin S, Leite ML, Allenbach G, et al. Phantom-based image quality assessment of clinical 99mTc-sestamibi SPECT protocols on CZT and conventional Anger cameras. EJNMMI Phys. 2016;3:11.
- Lindsay BD, Case JA, Dvorak RA, et al. ASNC Imaging Guidelines/SNMMI Procedure Standard for SPECT/CT Imaging. J Nucl Cardiol. 2018;25(5):1847-1960.
- World Health Organization (WHO). Global Initiative on Radiation Safety in Healthcare Settings: Technical Meeting Report. Geneva: WHO; 2023.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in nuclear medicine, cardiology, endocrine surgery and clinical radiopharmacy.
Medical Content
iMedic Nuclear Medicine Editorial Team - specialist physicians in nuclear medicine and cardiology with clinical experience in SPECT and SPECT/CT imaging
Medical Review
iMedic Medical Review Board - independent panel verifying accuracy against EMA SmPC, FDA label, EANM and SNMMI guidelines, and ICRP dosimetry publications
Radiopharmacy Review
iMedic Radiopharmacy Team - specialists in radiolabeling, quality control, radiation protection and good radiopharmacy practice (cGRPP)
Accessibility & SEO
iMedic Digital Health Team - ensuring WCAG 2.2 AAA compliance and optimal search visibility
All content follows the GRADE evidence framework and is reviewed according to international medical guidelines. iMedic receives no commercial funding from pharmaceutical or radiopharmaceutical companies.